The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 349.85 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...